Member login

Forgot Password?

By using the members area you have already agreed to share your personal information with the BGMA/BBA so that you can access the members materials. We will store your details only as long as you are a member. Your personal information will not be shared any affiliated companies or third parties. For more information about our Privacy Policy, click here.

Return to login
Back to News index

Reaction to Competition and Markets Authority (CMA) investigation into alleged anti-competitive agreements - consultation on commitments

Following the update by the CMA on August 14th, 2019, Warwick Smith, Director General of the British Generic Manufacturers Association (BGMA), said: "Competition between suppliers of essentially the same medicine is what drives value for the NHS from generic medicines. We condemn any anti-competitive behaviour which undermines competition and thus reduces the benefits to the NHS and to patients of the use of generic medicines."